

Divisional of U.S. Serial No. 08/894,327

Atty. Dkt. No.: 02973.00031

Page 3

Applicant requests that the computer readable form of the Sequence Listing be obtained from the parent file U.S. Serial No. 08/894,327. Applicants believe that the paper copy of the Sequence Listing attached hereto and the computer readable copy of the Sequence Listing found in the parent application U.S. Serial No. 08/894,327 are the same as the Sequence Listing originally disclosed in the specification and contain no new matter relative to the subject application as originally filed.

REMARKS

Claims 23-26 are pending in this application. A marked-up set of amended claims 23-26 are enclosed. Applicant respectfully requests examination on the merits of the pending claims.

Respectfully submitted,



Date: April 11, 2001

Ajay Pathak
Registration No. 38,266

BANNER & WITCOFF, LTD.
1001 G Street, N.W., 11th Floor
Washington, DC 20001
Tel: (202) 508-9100
Fax: (202) 508-9299

Attachment: Sequence Listing (Replacement Pages 31-40)
Marked-up Set of Amended Claims

AP:lab
386067_1.DOC

Divisional of U.S. Serial No. 08/894,327
Atty. Dkt. No.: 02973.00031
Page 4

Marked-up Set of Amended Claims

IN THE CLAIMS:

Claims 23 and 24 have been amended as follows:

23. (AMENDED) A method of treating an individual for a condition selected from the group consisting of exposure to DNA damaging agents, abnormal cell proliferation characteristic of psoriasis, atherosclerosis, cancer, and arterial restenosis, undesirable immune response accompanying rejection of a transplant and an autoimmune disease, comprising administering to the patient a pharmaceutical composition of claim 22 comprising a peptide having at least four sequential amino acids from a negative regulatory region which maps to residues 361-383 (SEQ. ID. No. 12) of p53, said peptide not being a subfragment of human p53, wherein said peptide activates DNA binding of wild-type p53 or a p 53 mutant containing a single amino acid substitution, said mutant selected from the group consisting of p53-ser²³⁹, p53-his²⁷³, p53-gln²⁴⁸, p53-trp²⁸², and p53-cys²⁷³, in a p53 DNA binding assay and a pharmaceutically acceptable carrier.
24. (AMENDED) A method for treating a patient having a tumor expressing a p53 mutant whose ability to bind DNA may be activated by peptides, modified peptides or peptidomimetics corresponding to all or a portion of the negative regulatory region which maps to residues 361-383 of p53, said method comprising administering to said patient a pharmaceutical composition according to claim 22comprising a peptide having at least four sequential amino acids from a negative regulatory region which maps to residues 361-383 (SEQ. ID. No. 12) of p53, said peptide not being a subfragment of human p53, wherein said peptide activates DNA binding of wild-type p53 or a p 53 mutant containing a single amino acid substitution, said mutant selected from the group consisting of p53-ser²³⁹, p53-his²⁷³, p53-gln²⁴⁸, p53-trp²⁸², and p53-cys²⁷³, in a p53 DNA binding assay and a pharmaceutically acceptable carrier.